Absent federal action, states take the lead on curbing drug costs image

The Washington Post, September 29, 2017
By Shefali Luthra, quoting Rachel E. Sachs (Academic Fellow Alumna)

Links

Read the full article

From the article:

Critics see these tailored efforts as falling short or potentially opening other loopholes. Requiring companies to report prices past a certain threshold, for example, might encourage them to consistently set prices just below that level. Maryland’s law is noteworthy because it includes a fine for drugmakers if price increases are deemed excessive — though a $10,000 fine is likely nominal for the billion-dollar industry, suggested Rachel Sachs, an associate law professor at Washington University, who researches drug regulations.

Read more here!

fda health care finance health law policy pharmaceuticals rachel sachs regulation